Norbert Riedel, Ph.D.
President and Chief Executive Officer, Aptinyx
Norbert Riedel, Ph.D., is president and chief executive officer of Aptinyx Inc., a biopharmaceutical company, where he also serves as a member of the board of directors.
Dr. Riedel was formerly president and chief executive officer of Naurex Inc., the predecessor company acquired by Allergan and from which Aptinyx and its technology were spun out. Prior to Naurex, he served in various roles at Baxter International Inc., most recently as corporate vice president and chief science and innovation officer. Previously, he was head of worldwide biotechnology and held a number of scientific management positions at Hoechst-Marion Roussel (now Sanofi). He is an adjunct professor at Boston University School of Medicine and Northwestern University’s Feinberg School of Medicine.
Dr. Riedel serves on the board of directors of Jazz Pharmaceuticals plc, Eton Pharmaceuticals, Inc. and the Illinois Biotechnology Innovation Organization. He served on the board of directors of Ariad Pharmaceuticals until the company was acquired. He is a member of the Austrian Academy of Sciences and served on Governor Pat Quinn’s Illinois Innovation Council.
Dr. Riedel holds a diploma in biochemistry and a Ph.D. in biochemistry from the University of Frankfurt.